CONTACT: Charity R. Clark, Chief of Staff, 802-828-3171
Agreement increases access to driver’s privilege cards
CONTACT: Charity Clark, Chief of Staff, 802-828-3171
AG Appoints Former Supreme Court Justices to Litigation Team
Contact: Lisa Jensen, Assistant Director, Consumer Assistance Program, 1-800-649-2424
Contact: Jamie Renner, Assistant Attorney General, (802) 828-3171
Consumer Guide to Long-Term Care Facilities Launched
Contact: Ryan P. Kane, Assistant Attorney General, (802) 828-3171
Contact: Jill Abrams, Director, Consumer Protection Unit, 802-828-3171
Lawsuit Alleges Violations of Consumer Protection Act, Unjust Enrichment, Public Nuisance
Contact: Jill Abrams, Director Consumer Protection Unit, 802-828-3171
Attorney General T.J. Donovan today filed a lawsuit against two distributors of opiates, Cardinal Health Inc. and McKesson Corporation. The lawsuit, filed in Chittenden Superior Court, alleges that Defendants committed unfair and deceptive acts in violation of the Vermont Consumer Protection Act and alleges claims of negligence and public nuisance. The State also contends that these distributors fraudulently concealed their unlawful conduct.
VSAC and Attorney General warn of scammers posing as student loan servicers
Attorney General T.J. Donovan joined Vermont Student Assistance Corporation (VSAC) to warn Vermonters about scams involving student loans. Scammers pose as student loan servicers, debt relief companies, document preparation companies or say that you may be eligible for a student loan forgiveness program.
Contact: Jill Abrams, Director, Consumer Protection Unit, (802) 828-1106
AG Alleges Deceptive and Unfair Acts and Public Nuisance
Vermont Attorney General T.J. Donovan announced that today his office filed a lawsuit against the pharmaceutical company Purdue Pharma. The lawsuit alleges violations of the Vermont Consumer Protection Act and public nuisance law concerning Purdue’s marketing and promotion of opioids. Purdue is the manufacturer of Oxycontin.
Attorney General Charity Clark today joined a multistate coalition to challenge the decision issued by the U.S. District Court for the Northern District of Texas that could restrict medication abortion access nationwide. The amicus brief, filed in the U.S. Court of Appeals for the Fifth Circuit, urges the court to stay pending appeal of the district court’s ruling, which if allowed to take effect would halt the over two-decades old approval from the U.S. Food and Drug Administration (FDA) of the medication abortion drug mifepristone.
